Back to list
BCG Strain Comparison
University of North Carolina at Chapel Hill
Description
This study will evaluate differences and effectiveness of two treatments on bladder cancer. Patients with newly diagnosed High Grade Non Muscle Invasive Bladder cancer who meet qualifications will be treated with standard BCG treatment or with Tokyo-172 BCG.
Keywords:
Cancer
Category:
Drug or Biologic
Qualifications
Age
18 - 99 years
Gender
Any
Study Population
Males and Females 18 and over with Bladder Cancer
Investigator
Matthew Nielsen
Associate Professor
Urology - Clinic
Recruitment Period End
September 30, 2023
Location
Primary Location
UNC Urology Clinic
101 Manning Dr #2, Chapel Hill, NC 27514, USA
Study Qualifications
Gender Any
Age Range 18 - 99 years
Participant qualification(s) Must have confirmed high grade non muscle invasive bladder cancer, All visible bladder tumors removed within 30 days prior to registration in study
Not eligible if: Cannot have any renal or ureter cancer involvement. Cannot have had prior treatment with BCG
Age Range 18 - 99 years
Participant qualification(s) Must have confirmed high grade non muscle invasive bladder cancer, All visible bladder tumors removed within 30 days prior to registration in study
Not eligible if: Cannot have any renal or ureter cancer involvement. Cannot have had prior treatment with BCG
Number of Visits
- » 20 In person visit(s)
1 Screening, 19 Clinic
» 0 Remote visit(s)Participation Period
60 months
